BioPharma Resources

Drug Trial Radar · NCT07673107

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor

A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

94

Planned (sponsor's estimate)

Start

Jun 23, 2026

Primary completion

Nov 2028

Study completion Nov 2028

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating. This study will assess if AGN-151607-DP is safe and effective by assessing adverse events and change in disease activity in adult participants with UL ET. AGN-151607-DP is an investigational drug being developed to treat UL ET. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 94 adult participants with upper limb essential tremor will be enrolled in approximately 40 sites in the United States/Canada. Participants will receive intramuscular injections of AGN-151607-DP or matching placebo. Duration of the study is approximately 72 weeks. The effect of the treatment will be checked by completion of questionnaires and side effects will be monitored by medical assessments.

Conditions

  • Upper Limb Essential Tremor

Interventions

  • AGN-151607-DPDrug

    Intramuscular Injection

  • Placebo for AGN-151607-DPDrug

    Intramuscular Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in The Essential Tremor Rating Assessment Scale (TETRAS)Time frame: 72 weeks
  2. Number of Participants with Adverse Events (AEs)Time frame: 72 weeks

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • The Neurology Center of Southern California - Carlsbad /ID# 278194

    Carlsbad, California · Recruiting

  • Neuro Pain Research Center /ID# 277899

    Fresno, California · Recruiting

  • Neurology Center Of North Orange County /ID# 278490

    Fullerton, California · Recruiting

  • New England Institute for Clinical Research /ID# 277315

    Stamford, Connecticut · Recruiting

  • Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277079

    Boca Raton, Florida · Recruiting

  • Charter Research - Winter Park /ID# 277875

    Orlando, Florida · Recruiting

  • Emerald Coast Neurology /ID# 277898

    Pensacola, Florida · Recruiting

  • Kansas Institute of Research /ID# 277068

    Overland Park, Kansas · Recruiting

  • Dent Neurologic Institute - Amherst /ID# 277242

    Amherst, New York · Recruiting

  • True North Neurology /ID# 278118

    Commack, New York · Recruiting

  • Neurology - Triad /ID# 277088

    Winston-Salem, North Carolina · Recruiting

  • Mount Carmel Health System /ID# 278234

    New Albany, Ohio · Recruiting

  • Veracity Neuroscience /ID# 277081

    Memphis, Tennessee · Recruiting

  • Texas Neurology /ID# 277067

    Dallas, Texas · Recruiting

  • Lone Star Neurology /ID# 278266

    Frisco, Texas · Recruiting

  • Houston Methodist Hospital /ID# 277326

    Houston, Texas · Recruiting

  • University of Virginia /ID# 278191

    Charlottesville, Virginia · Recruiting

  • Inland Northwest Research /ID# 277077

    Spokane, Washington · Recruiting

  • Center For Neurological Disorders /ID# 277048

    Greenfield, Wisconsin · Recruiting

  • True North Clinical Research /ID# 277130

    Halifax, Nova Scotia, Canada · Recruiting

  • Centre de Recherche St-Louis /ID# 277106

    Lévis, Quebec, Canada · Recruiting

  • Genge Partners /ID# 277096

    Pointe-Claire, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.